Journal Article10.1097/00130404-200211000-00010
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
Thomas A. Buchholz,David N. Stivers,James Stec,Mark Ayers,Edward Clark,Andrew Bolt,Aysegul Sahin,W. Fraser Symmans,Kenneth R. Hess,Henry Mark Kuerer,Vicente Valero,Gabriel N. Hortobagyi,Lajos Pusztai +12 more
108
TL;DR: This is the first report to show global gene expression changes during chemotherapy in a human solid tumor and a remarkable diversity in transcriptional response was observed for individual cases.
read more
Abstract: PURPOSE The purpose of this study was to analyze global gene expression changes in serial tumor core biopsy specimens taken during neoadjuvant chemotherapy for primary breast cancer. PATIENTS AND METHODS Core biopsy specimens from tumors were obtained before treatment and 24 and/or 48 hours after treatment from 21 women who were beginning chemotherapy for breast cancer. RNA was extracted, and radiolabeled complementary DNA was synthesized. The complementary DNA probes were hybridized to high-density microarray membranes that contained more than 25,000 human sequence clones. Hierarchical cluster analysis was used to compare the degree of similarity between expression profiles. RESULTS Twenty-five (45%) of the 56 available core specimens yielded sufficient quantity and quality RNA for microarray analysis. Microarray profiles were performed only on samples from patients with pretreatment and posttreatment specimens, resulting in serial data sets for five patients (14 specimens). The serial samples from individual patients clustered more closely than the samples taken from different patients. Analyses of the variance of individual gene expression showed that there were significantly fewer genes with fivefold differences in expression in an individual tumor at different times (average, 359 genes) versus pretreatment samples of different tumors (average, 732 genes). Patients with a good pathological response to treatment had gene patterns that clustered distinctly from those of poor responders. Significant transcriptional response occurred in all patients during therapy. Surprisingly, all patients had different genes change after chemotherapy, with no single gene having a significant expression change in all five patients. D I S C U S S I O N This is the first report to show global gene expression changes during chemotherapy in a human solid tumor. Comprehensive gene expression profiles of more than 25,000 genes can be obtained from core biopsy specimens. A remarkable diversity in transcriptional response was observed for individual cases. Further data are needed to determine whether gene profiling can predict response to chemotherapy.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Soonmyung Paik,Gong Tang,Steven Shak,Chungyeul Kim,Joffre B. Baker,Wanseop Kim,Maureen T. Cronin,Frederick L. Baehner,Drew Watson,John Bryant,Joseph P. Costantino,Charles E. Geyer,D. Lawrence Wickerham,Norman Wolmark +13 more
TL;DR: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
2.6K
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
TL;DR: The frontline drug doxorubicin has been used for treating cancer for over 30 years but causes toxicity to most major organs, especially life‐threatening cardiotoxicity, which forces the treatment to become dose‐limiting.
2.3K
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
Nikita Makretsov,David G. Huntsman,Torsten O. Nielsen,Erika Yorida,Michael Peacock,Maggie C.U. Cheang,Sandra E. Dunn,Malcolm Hayes,Matt van de Rijn,Chris Bajdik,C. Blake Gilks +10 more
TL;DR: This work demonstrates that hierarchical clustering of immunostaining data by using multiple markers can group breast cancers into classes with clinical relevance and is superior to the use of individual prognostic markers.
218
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
Claudia Arce,Carlos Pérez-Plasencia,Aurora Gonzalez-Fierro,Erick de la Cruz-Hernandez,Alma Revilla-Vázquez,Alma Chavez-Blanco,Catalina Trejo-Becerril,Enrique Pérez-Cárdenas,Lucia Taja-Chayeb,Enrique Bargallo,Patricia Villarreal,T. Ramirez,Teresa Vela,Myrna Candelaria,Maria F. Camargo,Elizabeth Robles,Alfonso Dueñas-González +16 more
TL;DR: Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors in breast cancer patients, and appears to increase the efficacy of chemotherapy.
Cancer cell adaptation to chemotherapy.
Federica Di Nicolantonio,Stuart Mercer,Louise A. Knight,Francis G Gabriel,Pauline A. Whitehouse,Sanjay Sharma,Augusta Fernando,Sharon Glaysher,Silvana Di Palma,Penny Johnson,Shaw Somers,Simon Toh,Bernard Higgins,Alan Lamont,Tim J. Gulliford,Jeremy Hurren,Constantinos Yiangou,Ian A. Cree +17 more
TL;DR: It is suggested that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material.
References
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
12.4K
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van't Veer,Hongyue Dai,Marc J. van de Vijver,Yudong D. He,Augustinus A. M. Hart,Mao Mao,Hans Peterse,Karin van der Kooy,Matthew J. Marton,Anke T. Witteveen,George J. Schreiber,Ron M. Kerkhoven,Christopher J. Roberts,Peter S. Linsley,René Bernards,Stephen H. Friend +15 more
TL;DR: DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
TL;DR: IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.
2.1K
Gene-Expression Profiles in Hereditary Breast Cancer
Ingrid Hedenfalk,David Duggan,Yi Chen,Michael D. Radmacher,M. Bittner,Richard M. Simon,P. Meltzer,Barry A. Gusterson,Manel Esteller,O. P. Kallioniemi,Benjamin S. Wilfond,Åke Borg,J.M. Trent,Mark Raffeld,Zohar Yakhini,Amir Ben-Dor,Edward R. Dougherty,Juha Kononen,Lukas Bubendorf,W Fehrle,Stefania Pittaluga,Sofia Gruvberger,Niklas Loman,Oskar T. Johannsson,Håkan Olsson,Guido Sauter +25 more
TL;DR: Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancersWith BRCa2 mutations, the results suggest that a heritable mutation influences the gene-expression profile of the cancer.
1.7K
Related Papers (5)
Marc J. van de Vijver,Yudong D. He,Laura J. van't Veer,Hongyue Dai,Augustinus A. M. Hart,D.W. Voskuil,George J. Schreiber,Johannes L. Peterse,Christopher J. Roberts,Matthew J. Marton,Mark Parrish,Douwe Atsma,Anke T. Witteveen,Annuska M. Glas,Leonie J. M. J. Delahaye,Tony van de Velde,Harry Bartelink,Sjoerd Rodenhuis,Emiel J. Th. Rutgers,Stephen H. Friend,René Bernards +20 more
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more